Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;22(1):53-58.
doi: 10.1016/j.clcc.2022.12.001. Epub 2022 Dec 8.

Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan

Seiya Sato  1 , Yoshiaki Nakamura  2 , Eiji Oki  3 , Takayuki Yoshino  4
Affiliations
Free article
Review

Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan

Seiya Sato et al. Clin Colorectal Cancer. 2023 Mar.
Free article

Abstract

The body of evidence supporting the utility of the detection of molecular residual disease (MRD) in resected colorectal cancer (CRC) using circulating tumor DNA (ctDNA) analysis is rapidly growing. Furthermore, this evidence provides the rationale for escalation and de-escalation adjuvant chemotherapy (ACT) strategies using ctDNA MRD analysis. This has led to various randomized clinical trials, and CIRCULATE-Japan is one of the largest of these trial platforms. In this review, we provide an overview of the potential utility of ctDNA-based MRD detection for escalation and de-escalation ACT approaches. Furthermore, we highlight the feasibility using ctDNA clearance as a surrogate endpoint for ACT trials in patients with resected CRC, based on findings of the CIRCULATE-Japan project.

Keywords: Adjuvant therapy; Circulating tumor DNA; Liquid biopsy; MRD; Recurrence monitoring.

PubMed Disclaimer

Conflict of interest statement

Disclosure S.S. declares no conflicts of interest. Y.N. reports honoraria from Chugai Pharmaceutical, Merck Biopharma, and Guardant Health AMEA and research grants from Taiho Pharmaceutical, Chugai Pharmaceutical, Guardant Health, Genomedia, Daiichi Sankyo, Seagen, and Roche Diagnostics outside the submitted work. E.O. reports research funding from Guardant Health and Verily Life Science, and speaker's bureau at Chugai Pharmaceutical, Eli Lilly, Merck biopharm, Bayer, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, and Bristol Myers. T.Y. reports grants from Sanofi, Daiichi Sankyo, PAREXEL, Pfizer, Amgen, Genomedia, Sysmex, Nippon Boehringer; grants and honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, MSD; Chugai Pharmaceutical; and honoraria from Eli Lilly, Merck Biopharma, and Bayer Yakuhin.

Publication types

MeSH terms